Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent

Journal of Thoracic Oncology

Volumn 8, Issue 1, 2013, Pages 45-51

  Conklin, Chris M J ^a   Craddock, Kenneth J ^b   Have, Cherry ^b   Laskin, Janessa ^a   Couture, Christian ^c   Ionescu, Diana N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Anaplastic lymphoma receptor tyrosine kinase rearrangement; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; TISSUE MICROARRAY; TISSUE SECTION;

EID: 84871986190     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318274a83e     Document Type: Article

References (29)

1. Kamangar F, Dores GM, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across fve continents: defning priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
2. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
3. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348-354.
4. Soda M, Choi YL, Enomoto M, et al. Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
5. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 2004;304:1497-1500.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 2004;350:2129-2139.
7. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-1780.
8. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lym-phoma kinase: signalling in development and disease. Biochem J 2009;420:345-361.
9. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-515.
10. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
11. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and tran-scriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-1158.
12. Popat S, Gonzalez D, Min T, et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer 2012;75:300-305.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
14. Koivunen J P, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and effcacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
15. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
16. Ou SH, Bazhenova L, Camidge DR, et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010;5:2044-2046.
17. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:18s.
18. Camidge DR, Bang YJ, Kwak EL, Shaw AT, Iafrate AJ, Maki RG. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29:abstr 2501.
19. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with geftinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-844.
20. Sequist LV, Martins RG, Spigel D, et al. First-line geftinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
21. Choi YL, Soda M, Yamashita Y, et al.; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-1739.
22. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic signifcance. Am J Surg Pathol 2007;31:26-32.
23. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
24. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
25. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
26. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012;106:1100-1106.
27. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288-292.
28. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion onco-kinase identifed by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
29. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fuorescence in situ hybridization. J Thorac Oncol 2011;6:466-472.